Imunofan as adjunctive treatment for negative symptoms in schizophrenia — RU2195957C2
V. V. Barzakov, A. P. Muzychenko, S. I. Dmitrenkov · 2003 · RU2195957C2 · patent family 20242171
Published 2003-01-10.
Reported patent results
Reported findings
The patent reports a positive outcome in 20 of 33 patients (60.6%). It describes no comparator.
Patent case series in people with schizophrenia and negative symptoms. Psychotropic medication continued. The specification describes 1 mL of 0.005% Imunofan intramuscularly daily for 15 days.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported positive outcome | 20/33 (60.6%) | Patent case series. No standardized response definition, comparator or uncertainty estimate. |
| Illustrative case at six months | The authors describe improved social and occupational function. | Single case example while on continuing psychiatric treatment. |
| Adverse effects | None reported in the specification. | The filing does not describe systematic safety monitoring. |
The filing gives no controlled estimate of Imunofan’s effect. Its relationship to Muzychenko’s 2002 comparison is unknown, so the reports cannot be pooled.
Source for these results ↗ · Reviewed 2026-11-10
Patent claims and provenance
Use. The filing claims intramuscular Imunofan alongside psychotropic treatment for negative symptoms of schizophrenia.
The patent describes an uncontrolled series. Overlap with the 2002 comparison cited in a separate dissertation is unresolved.
- Publication
- RU2195957C2 ↗ · 2003-01-10
- Earliest priority / filing
- 2000-11-17 / 2000-11-17
- Original applicant / assignee
- Moscow Research Institute of Psychiatry
- Indexed status
- Not shown; official status unverified · checked 2026-11-10
- Patent family
- 20242171 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Способ лечения негативных расстройств при шизофрении
Inventors: V. V. Barzakov; A. P. Muzychenko; S. I. Dmitrenkov.
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The patent describes an uncontrolled series. Overlap with the 2002 comparison cited in a separate dissertation is unresolved.
- The filing gives no controlled estimate of Imunofan’s effect. Its relationship to Muzychenko’s 2002 comparison is unknown, so the reports cannot be pooled.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Available format: Original patent text and indexed metadata
Material reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related publications may cover the same research program or participants.
Source access
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Source reviewed 2026-11-10.
Source type: Patent publication
Citation and original source
Original source: V. V. Barzakov, A. P. Muzychenko, S. I. Dmitrenkov. Imunofan as adjunctive treatment for negative symptoms in schizophrenia — RU2195957C2 RU2195957C2 · patent family 20242171 2003.
Molekul research summary: https://molekul.io/research/patent-ru2195957c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry